Bleximenib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Bleximenib
- Molecular weight
- 599.8
- Structure (SMILES)
- CCN(C(=O)c1cc(F)ccc1Oc1nncnc1N1CCC2(C1)CN([C@H](CCCN(C)CCOC)C(C)C)C2)C(C)C
- bleximenib
- Bleximenib
- bleximenib [INN]
- BLEXIMENIB [USAN]
- Bleximenib [WHO-DD]
- bleximenib inn
- bleximenib usan
- bleximenib who dd
- jnj 75276617
- JNJ-75276617
- CAS registry numbers
- 2654081-35-1
- ChEMBL ID
- CHEMBL5314509
- InChIKey
- PDUGAXSIWNMIBQ-HHHXNRCGSA-N
- PubChem compound IDs
- 156498110
- FDA ingredient codes (UNII)
- DCN5WEN78T
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- bleximenib
- Type
- Synthetic organic
- Drug name stem
- -menib
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010643
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 3
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 0
- Polar surface area
- 87.16
- Calculated partition coefficient (ALogP)
- 4.57
- Calculated partition coefficient (XLogP)
- 4.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 15
- Heavy atoms
- 43
- Molecular formula
- C32H50FN7O3
- Monoisotopic mass
- 599.39591664
- Natural product
- No
- Recorded assays
- 8
- Active assays
- 8
Active assay types
- Confirmatory
Related records
Trials (7)
- A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
- Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee